Vadim Koshkin, Assistant Professor at University of California, San Francisco, shared a post on X/Twitter:
”Our recent work in European Urology Focus with Jason Brown, Case Comp Cancer Center highlighting a Grey Zone in metastatic urothelial carcinoma after enfortumab vedotin/pembrolizumab.
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.”
Source: Vadim Koshkin/X